Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
US12156887B2 · kind B2 · utility
0Cited by
11References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2019 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Aug 5, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.